Neumora Therapeutics, Inc. (NMRA)
| Market Cap | 411.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -236.93M |
| Shares Out | 182.69M |
| EPS (ttm) | -1.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,071,651 |
| Open | 2.220 |
| Previous Close | 2.220 |
| Day's Range | 2.160 - 2.300 |
| 52-Week Range | 0.611 - 3.650 |
| Beta | 3.12 |
| Analysts | Buy |
| Price Target | 7.50 (+233.33%) |
| Earnings Date | May 7, 2026 |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for NMRA stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 233.33% from the latest price.
News
Neumora Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Four clinical programs are advancing, with major data readouts for navacaprant in MDD expected in Q2 and promising progress in Alzheimer's agitation, obesity, and muscarinic schizophrenia assets. Regulatory flexibility and robust financials support multiple upcoming catalysts.
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targ...
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeu...
Neumora Therapeutics Earnings Call Transcript: Q4 2025
Significant clinical progress in 2025 included positive NMRA-511 and NMRA-215 data, full enrollment of Navacaprant phase III studies, and advancement of NMRA-898 for schizophrenia. Cash runway extends into Q3 2027, with multiple clinical milestones expected in 2026.
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targ...
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.
Neumora Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
New phase I-B data for NMRA-511 in Alzheimer's agitation show strong efficacy and safety, with plans for higher dosing and pivotal studies. NMRA-215 is advancing for obesity with a focus on CNS penetration, and key pipeline updates are expected mid-year. Operations are funded into Q3 2027.
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targe...
Neumora Therapeutics Transcript: Study Result
Phase IB data for NMRA-511 in Alzheimer's agitation showed clinically meaningful reductions in agitation, especially in patients with elevated anxiety, and a favorable safety profile. Plans include higher dose studies, a once-daily formulation, and a Phase II/III trial.
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to co...
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specif...
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ: NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.
Neumora Therapeutics Transcript: Stifel 2025 Healthcare Conference
Six clinical readouts are expected in the next year across four fully funded programs, including first-in-human studies for a novel NLRP3 inhibitor and advanced trials in Alzheimer's agitation and antipsychotic therapies. Enhanced study designs and operational rigor support a robust neuroscience pipeline.
Neumora Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Multiple clinical programs are advancing, including NMRA-215 for obesity, which showed semaglutide-like weight loss in preclinical studies and will enter human trials in 2026. Key Alzheimer’s and MDD studies are also progressing, with several major data readouts expected over the next 12 months.
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study ...
Neumora Therapeutics to Participate in Upcoming Conferences in November
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that...
Neumora Therapeutics Transcript: R&D Day 2025
NMRA-215 demonstrated class-leading weight loss and biomarker improvements in preclinical obesity models, with clinical studies planned for 2026. NMRA-511 and Navacaprant are advancing toward key data readouts in Alzheimer's agitation and MDD, respectively, with a strong cash runway supporting multiple upcoming milestones.
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglut...
Neumora Therapeutics to Host Virtual R&D Day on October 27
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that...
Neumora Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The event highlighted progress on a CNS-penetrant NLRP3 inhibitor for obesity, with preclinical data due this year and clinical trials planned for 2026. Updates included a dual M4 PAM franchise for neuropsychiatric disorders and operational improvements in ongoing studies.
Neumora Therapeutics to Participate in Upcoming Conferences in September
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs tha...
Neumora Therapeutics Earnings Call Transcript: Q2 2025
Prioritized obesity as lead indication for NMRA-215, with strong pipeline progress and up to six clinical data readouts expected in the next 18 months. Ended Q2 2025 with $217.6M in cash, supporting operations into 2027 and all key milestones.
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioriti...